Barriers to Risk Stratification Accuracy in Ischemic Heart Disease in Women: The Role of Non-Obstructive Coronary Artery Disease.

abstract：:The skin is often introduced as the largest organ of the human body which - being uniquely exposed to external stress - faces several types of challenges, from physical, chemical, biological, and immunological origin. Therefore, the skin is also a site where inflammation, oxidative stress and cellular damage occurs re...

journal_title：Current pharmaceutical design

authors： Szabo IL,Kenyeres A,Szegedi A,Szollosi AG

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Familial Hypercholesterolaemia (FH) is an autosomal-dominant genetic disease and represents the most common genetic disorder: heterozygous 1/250 births, homozygous 1/300, 000 births. FH is characterized by high to very high low-density lipoprotein cholesterol (LDL-C), which is the main cause of increased inc...

journal_title：Current pharmaceutical design

authors： Viigimaa M,Heinsar S,Lovic D,Katsimardou A,Piperidou A,Duishvili D

更新日期：2018-01-01 00:00:00

abstract：:We have gained considerable insight and understanding about the etiology, embryogenesis of the myocardium, genetic background, diagnosis and outcome of left ventricular non-compaction (LVNC) over the last 2 decades. LVNC has a distinct morphological appearance with a thickened, two-layered myocardium consisting of an ...

journal_title：Current pharmaceutical design

authors： Ganame J

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND/OBJECTIVE:KRAS-mutant colorectal cancers (CRC) are tumors that are associated with poor prognosis. However, no effective treatments are available to target them. Therefore, we designed and synthesized novel chalcone analogs, small organic molecules, to investigate their effects on KRAS-mutant CRC cells. MET...

journal_title：Current pharmaceutical design

authors： Mahmoud A,Elkhalifa D,Alali F,Al Moustafa AE,Khalil A

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:The last few decades have witnessed enormous advancements in the field of Pharmaceutical drug, design and delivery. One of the recent developments is the advent of 3DP technology. It has earlier been successfully employed in fields like aerospace, architecture, tissue engineering, biomedical research, medica...

journal_title：Current pharmaceutical design

authors： Mirza MA,Iqbal Z

更新日期：2018-01-01 00:00:00

abstract：:Inhibition of carbonic anhydrase (CA, EC 4.2.1.1) isoforms present in the eyes (CA I, II, IV and XII), with sulfonamides such as acetazolamide, methazolamide, ethoxzolamide and dichlorophenamide, is still widely used for the systemic treatment of glaucoma. The mechanism of action of these drugs consists in inhibition ...

journal_title：Current pharmaceutical design

authors： Mincione F,Scozzafava A,Supuran CT

更新日期：2008-01-01 00:00:00

abstract：:Telomerase is a specialized enzymatic complex responsible for the synthesis of telomeric repeats 5'-TTAGGG-3' localized at the ends of eukaryotic chromosomes. This mechanism prevents shortening of telomeres after each cell division. The enzyme is detected in about 85% of human tumors, but it is not expressed in normal...

journal_title：Current pharmaceutical design

authors： Romaniuk A,Kopczynski P,Ksiazek K,Rubis B

更新日期：2014-01-01 00:00:00

abstract：:Inflammatory and infectious diseases include many different clinical conditions not often well recognised and characterized with conventional radiology and biochemical tests. Radiological techniques (TC, MRI, US) show anatomical changes that usually occur in chronic stages of the disease leading to a delayed diagnosis...

journal_title：Current pharmaceutical design

authors： Signore A,Lauri C,Galli F

更新日期：2014-01-01 00:00:00

abstract：:The triggering receptor expressed on myeloid cells (TREM)-1 is a member of the Ig-like immunoregulatory receptor family and a major amplifier of innate immune responses. TREM- 1 has been implicated in the development and perpetuation of a number of inflammatory disorders, and soluble TREM-1 levels are a clinically val...

journal_title：Current pharmaceutical design

authors： Bosco MC,Raggi F,Varesio L

更新日期：2016-01-01 00:00:00

abstract：:Reduced levels of high-density lipoprotein cholesterol (HDL) are associated with a substantially increased risk of coronary disease and cardiovascular events. Furthermore, numerous studies have suggested that HDL may exert several potentially important antiatherosclerotic and endothelial-protective effects. In particu...

journal_title：Current pharmaceutical design

authors： Besler C,Heinrich K,Riwanto M,Lüscher TF,Landmesser U

更新日期：2010-05-01 00:00:00

abstract：:DARPins (designed ankyrin repeat proteins), new kinds of binding proteins, have the potential to overcome the defects of monoclonal antibodies, and hence may become the alternatives to antibodies and generate a novel therapeutic approach. DARPins can be selected to bind any given target proteins with high affinity and...

journal_title：Current pharmaceutical design

authors： Wu X,Shi Y,Ren P,Wang D,Li G

更新日期：2013-01-01 00:00:00

abstract：:Medicinal inorganic chemistry plays an important role in exploring the properties of metal ions for the designing of new drugs. The field has been stimulated by the success of cis-platin, the world best selling anticancer drug and platinum complexes with reduced toxicity, oral activity and activity against resistant t...

journal_title：Current pharmaceutical design

authors： Sirajuddin M,Ali S

更新日期：2016-01-01 00:00:00

abstract：:Human tryptase is a structurally unique and mast cell specific trypsin-like serine protease. Recent biological and immunological investigations have implicated tryptase as a mediator in the pathology of numerous allergic and inflammatory conditions including rhinitis, conjunctivitis, and most notably asthma. A growing...

journal_title：Current pharmaceutical design

authors： Rice KD,Tanaka RD,Katz BA,Numerof RP,Moore WR

更新日期：1998-10-01 00:00:00

abstract：:The oncoproteins MDM2 and MDMX negatively regulate the activity and stability of the p53 tumor suppressor, directly contributing to the development and progression of many tumors harboring wild type p53. Antagonizing MDM2 and MDMX to activate the p53 pathway has thus become an attractive new strategy for anticancer dr...

journal_title：Current pharmaceutical design

authors： Zhan C,Lu W

更新日期：2011-01-01 00:00:00

abstract：:Stem cell therapy heralds a new chapter in cardiovascular regenerative medicine. Cardiovascular implants are often used in both surgery and interventional cardiology. Cardiovascular stents are utilized in percutaneous coronary interventions (PCI), and are classified as either bare metal stents (BMS) or drug-eluting st...

journal_title：Current pharmaceutical design

authors： Tan A,Sumpio BE,Lee S,Seifalian AM

更新日期：2010-01-01 00:00:00

abstract：BACKGROUND:Ximelagatran has been approved in Europe for VTE prophylaxis in orthopedic surgery at fixed doses and without laboratory monitoring. Aim of the study was to evaluate safety and efficacy of ximelagatran in a meta-analysis of prophylaxis and/or treatment randomized controlled trials. METHODS:Absolute risk of ...

journal_title：Current pharmaceutical design

authors： Iorio A,Guercini F,Ferrante F,Nenci GG

更新日期：2005-01-01 00:00:00

abstract：:Single-agent therapy with molecularly targeted agents has shown limited success in tumor growth control, mainly because escape or resistance mechanisms are activated once a signalling molecule is inhibited. Rational combinations of target-specific agents could counteract this response providing a useful strategy in ca...

journal_title：Current pharmaceutical design

authors： Porcelli L,Quatrale AE,Mantuano P,Silvestris N,Rolland JF,Biancolillo L,Paradiso A,Azzariti A

更新日期：2013-01-01 00:00:00

abstract：:Invasive fungal infections are a major cause of morbidity and mortality in immunosuppressed patients with fatality rates ranging from 30 % to 80 % in neutropenic patients. This results at least partly in difficulties obtaining a reliable and early diagnosis, followed by the fact that clinical symptoms are unspecific a...

journal_title：Current pharmaceutical design

authors： Lackner M,Lass-Flörl C

更新日期：2013-01-01 00:00:00

abstract：:Mechanical loading provides an anabolic stimulus for bone. More importantly, the mechanosensing apparatus in bone directs osteogenesis to where it is most needed for improving bone strength. The biological processes involved in bone mechanotransduction are poorly understood and further investigation of the molecular m...

journal_title：Current pharmaceutical design

authors： Turner CH,Robling AG

更新日期：2004-01-01 00:00:00

abstract：:In the brain, acetylcholine (ACh) is regarded as one of the major neurotransmitters. During the advancement of Alzheimer's disease (AD) cholinergic deficits occur and this can lead to extensive cognitive dysfunction and decline. Acetylcholinesterase (AChE) remains a highly feasible target for the symptomatic improveme...

journal_title：Current pharmaceutical design

authors： Kabir MT,Uddin MS,Begum MM,Thangapandiyan S,Rahman MS,Aleya L,Mathew B,Ahmed M,Barreto GE,Ashraf GM

更新日期：2019-01-01 00:00:00

abstract：:In the last two decades the development of efficient plant-based expression strategies and new concepts for the purification of recombinant proteins prompted the application of plant-derived vaccines for veterinary purposes. The expression of recombinant proteins in plants possesses advantages over conventional eukary...

journal_title：Current pharmaceutical design

authors： Phan HT,Floss DM,Conrad U

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:Neuroanatomical abnormalities, including cingulate cortex volume abnormalities, are a common feature in psychosis. However, the extent to which these are related to a vulnerability to psychosis, as opposed to the disorder per se, is less certain. AIM UND HYPOTHESES: The aim of the present study is to compare...

journal_title：Current pharmaceutical design

authors： Röthlisberger M,Riecher-Rössler A,Aston J,Fusar-Poli P,Radü EW,Borgwardt S

更新日期：2012-01-01 00:00:00

abstract：:The survival of patients with pulmonary arterial hypertension is closely related with right ventricular function. During the progression of right ventricular remodeling, energetic metabolism shifts from oxidative mitochondrial metabolism to glycolysis. In normal physiological conditions, cardiomyocytes use major sourc...

journal_title：Current pharmaceutical design

authors： Zhang R,Jing ZC

更新日期：2016-01-01 00:00:00

abstract：:In the present review, associations between traditional vascular risk factors (VRFs) and carotid intimamedial thickness progression (C-IMTp) as well as the effects of therapies for VRFs control on C-IMTp were appraised to infer causality between each VRF and C-IMTp. Cohort studies indicate that smoking, binge drinking...

journal_title：Current pharmaceutical design

authors： Frigerio B,Werba JP,Amato M,Ravani A,Sansaro D,Coggi D,Vigo L,Tremoli E,Baldassarre D

更新日期：2020-01-01 00:00:00

abstract：:Recent advances in the fabrication, characterization and application of micro- and nano-particles that possess a non-uniform internal structure are reviewed. The particle structures include core-shell particles, particles with multiple cores or a multi-layered structure, porous particles with both regular and random p...

journal_title：Current pharmaceutical design

authors： Čejková J,Štêpánek F

更新日期：2013-01-01 00:00:00

abstract：:Tumour resistance to anticancer agents remains a challenge in oncological practice, because it results in exposure to toxicities, unnecessary costs and, most importantly, delay of a potentially more effective treatment. Drug uptake by tumours may be impaired by several resistance pathways. Reasons for primary resistan...

journal_title：Current pharmaceutical design

authors： van der Veldt AA,Luurtsema G,Lubberink M,Lammertsma AA,Hendrikse NH

更新日期：2008-01-01 00:00:00

abstract：:Drug-drug interactions may occur when to combine two or more drugs and may cause some adverse events such as Cardiotoxicity, Central neurotoxicity, Hepatotoxicity, etc. Although a large number of researchers who are proficient in pharmacokinetics and pharmacodynamics have been engaged in drug assays and trying to find...

journal_title：Current pharmaceutical design

authors： Huang W,Li C,Ju Y,Gao Y

更新日期：2021-01-27 00:00:00

abstract：:Subjects affected by ischemic heart disease with non-obstructive coronary arteries constitute a population that has received increasing attention over the past two decades. Since the first studies with coronary angiography, female patients have been reported to have non-obstructive coronary artery disease more frequen...

journal_title：Current pharmaceutical design

authors： Bergami M,Scarpone M,Cenko E,Varotti E,Amaduzzi PL,Manfrini O

更新日期：2020-10-12 00:00:00

abstract：:The Hereditary Spastic Paraparesis (HSP) or Strumpell-Lorrain disease is a heterogeneous neurodegenerative disease of the spinal cord. It is genetically transmitted and characterized by a progressive muscle weakness, spasticity of the lower limbs and awkward gain. There is no specific pharmacological treatment. The ph...

journal_title：Current pharmaceutical design

authors： Riccardo M,Angela L,Angela D,Vita P,Giulio L,Pietroq F,Giancarlo I,Marisa M

更新日期：2016-01-01 00:00:00

abstract：:We herein reviewed the mechanism underlying the gastric hyperemic response following barrier disruption, with a focus on cyclooxygenase (COX) isozymes, prostaglandin (PG) E2, and capsaicin-sensitive afferent neurons. Mucosal damage was induced by exposing the stomach to 20 mM taurocholate (TC) with 50 mM HCl. The TC t...

journal_title：Current pharmaceutical design

authors： Takeuchi K,Takeeda M,Amagase K,Nakashima M

更新日期：2015-01-01 00:00:00